Dermata Therapeutics

Dermata Therapeutics is a San Diego-based company pivoting from prescription dermatology to a direct-to-consumer skincare model built on its Bioneedle and Spongilla technologies. Its first DTC product, Tome Foundational Treatment, is a topical skin-renewal product set for commercial launch in August 2026, with a clearing/acne treatment line under the same brand. The company's technology platform derives from freshwater sponge spicules for controlled micro-needling of the skin, and its pipeline previously included Phase 3 dry-eye and acne programs. With a lean cash position, the Tome launch is the company's key value inflection.